Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1β, and nuclear factor κB in trinitrobenzene sulphonic acid induced colitis in rats

Postgraduate Medical Journal

Volumn 82, Issue 964, 2006, Pages 130-135

  Song, M ^b   Xia, B ^a   Li, J ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; ENEMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESALAZINE; MESSENGER RNA; MYELOPEROXIDASE; TREFOIL FACTOR 3; TREFOIL PEPTIDE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYRATES; COLITIS; INTERLEUKIN-1; MALE; MESALAMINE; NEUROPEPTIDES; NF-KAPPA B; PEROXIDASE; RATS; RATS, WISTAR; RNA, MESSENGER; SULFONIC ACIDS; TRINITROBENZENES;

EID: 33144483637     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.037945     Document Type: Article

References (33)

1. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994;89:179-83.
2. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003;33:244-8.
3. Vernia P, Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40:305-7.
4. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various soecies. Physiol Rev 1989;70:567-90.
5. Clausen MR, Mortensen PB. Kinetic studies on the metabolism of short-chain fatty acids and glucose by isolated rat coloncytes. Gastroenterology 1994;106:423-32.
6. Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980;21:793-8.
7. Liu Q, Shimoyama T, Suzuki K, et al. Effect of sodium butyrate on reactive oxygen species generation by human neutrophils. Scand J Gastroenterol 2001;36:744-50.
8. Venkatraman A, Ramakrishna BS, Shaji RV, et al. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2003;285:177-84.
9. Tarrerias AL, Millecamps M, Alloui A, et al. Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats. Pain 2002;100:91-7.
10. Cavaglieri CR, Nishiyama A, Fernandes LC, et al. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci 2003;73:1683-90.
11. Luhrs H, Gerke T, Muller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002;37:458-66.
12. Lin J, Nadroo AM, Chen W, et al. Ontogeny and prenatal expression of trefoil factor 3/ITF in the human intestine. Early Hum Dev 2003;71:103-9.
13. Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:6694-702.
14. Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signaling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001;49:190-8.
15. Yu K, Jiang SF, Lin MF, et al. Extraction and purification of biologically active intestinal trefoil factor from human meconium. Lab Invest 2004;84:390-2.
16. Moro F, Levenez F, Durual S, et al. Secretion of the trefoil factor TFF3 from the isolated vascularly perfused rat colon. Regul Pept 2001;101:35-41.
17. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
18. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990;258:527-34.
19. Fedorak RN, Empey LR, MacArthur C, et al. Micoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 1990;98:615-25.
20. Krawitz JE, Sharon P, Stenson F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1995;87:1344-50.
21. Renes IB, Verburg M, Van Nispen DJ, et al. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int J Colorect Dis 2002;17:317-26.
22. Dossinger V, Kayademir T, Blin N, et al. Down-regulation of TFF expression in gastrointestinal cell lines by cytokines and nuclear factors. Cell Physiol Biochem 2002;12:197-206.
23. Fontaine V, Van der Meijden E, de Graaf J, et al. A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 2000;272:40-9.
24. Li J, Peef GW, Balzarano D, et al. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem 2001;276:18579-90.
25. Li X, Massa PE, Hanidu A, et al. IKKα, IKKβ, and NEMO/IKKγ are each required for the NF-κB-mediated inflammatory response program. J Biol Chem 2002;277:45129-40.
26. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000;275:3687-92.
27. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274:26448-53.
28. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kappaB and PPARalpha. J Nutr Biochem 2004;15:220-8.
29. Luhrs H, Gerke T, Boxberger F, et al. Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig Dis Sci 2001;46:1968-73.
30. Inan MS, Rasoulpour RJ, Yin L, et al. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 2000;118:724-34.
31. Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory κB protein α is inhibited by the short-chain fatty acid butyrate. Int J Colorect Dis 2001;16:195-201.
32. Loncar MB, Al-azzeh ED, Sommer PS, et al. Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. Gut 2003;52:1297-303.
33. Loncar MB, Al-azzeh ED, Romanska H, et al. Transcriptional control of TFF3 (intestinal trefoil factor) via promoter binding sites for the nuclear factor kappaB and C/EBPbeta. Peptides 2004;25:849-54.